Machine learning

● AI models, not dissimilar to ChatGPT in the field of languages, are designing new compounds and speeding up the pharmaceutical industry’s quest to develop new drugs.
● Building on traditional research and existing test data, the new AIs enable laboratories to gain time and optimise drug candidates’ chances of success in clinical trials.
● Deploying the power of reinforcement learning, the new machines can take into account innumerable parameters and evaluate the eligibility of compounds in just a few milliseconds.